Eupraxia Pharmaceuticals (EPRX) Expected to Announce Earnings on Thursday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is expected to release its results before the market opens on Thursday, November 6th. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.23) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Trading Down 3.0%

Shares of NASDAQ EPRX opened at $5.44 on Thursday. Eupraxia Pharmaceuticals has a 12 month low of $2.47 and a 12 month high of $7.19. The firm has a market capitalization of $195.62 million, a price-to-earnings ratio of -6.40 and a beta of 1.51. The business has a 50-day moving average of $5.63 and a 200-day moving average of $4.92.

Institutional Trading of Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its position in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after purchasing an additional 59,683 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EPRX. Cantor Fitzgerald began coverage on Eupraxia Pharmaceuticals in a research note on Thursday, July 24th. They issued an “overweight” rating and a $11.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.